NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
Authors:
- William G. WierdaWWWilliam G. Wierda
- John C. ByrdJBJohn C. Byrd
- Jeremy S. AbramsonJAJeremy S. Abramson
- Syed F. BilgramiSBSyed F. Bilgrami
- Greg BociekGBGreg Bociek
- Danielle BranderDBDanielle Brander
- Jennifer BrownJBJennifer Brown
- Asher A. Chanan-KhanACAsher A. Chanan-Khan
- Julio C. ChavezJCJulio C. Chavez
- Steve E. CoutreSCSteve E. Coutre
- Randall S. DavisRDRandall S. Davis
- Christopher D. FletcherCFChristopher D. Fletcher
Open Access
- 18 January 2019
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 17 (1) , 12-20
Abstract
Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.Keywords
This publication has 31 references indexed in Scilit:
- Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center ExperienceClinical Lymphoma Myeloma and Leukemia, 2018
- Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphomaAmerican Journal of Hematology, 2017
- Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novoHodgkin lymphomaAmerican Journal of Hematology, 2015
- Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationAmerican Journal of Hematology, 2014
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndromeJournal of Experimental Medicine, 2013
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter SyndromeClinical Lymphoma Myeloma and Leukemia, 2013
- NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcomeLeukemia, 2012
- Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B‐cell lymphomasHematological Oncology, 2009
- The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)Annals of Oncology, 2009
- Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chronic lymphocytic leukemiaCancer, 2003